Literature DB >> 11533075

Loss of heterozygosity at cylindromatosis gene locus, CYLD, in sporadic skin adnexal tumours.

N Leonard1, R Chaggar, C Jones, M Takahashi, A Nikitopoulou, S R Lakhani.   

Abstract

AIM: The gene for familial cylindromatosis (CYLD) has been localised to chromosome 16q, and has recently been cloned. Loss of heterozygosity (LOH) at 16q has also been demonstrated in sporadic cylindromas. The aim of this study was to investigate whether CYLD plays a role in the development of other skin appendage tumours.
METHODS: A total of 55 cases of skin adnexal tumours, comprising 12 different types, and a control group of 14 squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs) were studied. Three microsatellites (D16S407 (16p), D16S304 (16q), and D16S308 (16q)) were analysed for LOH after microdissection from paraffin wax embedded sections using laser capture microdissection.
RESULTS: In keeping with previous data, a proportion of cylindromas exhibited LOH at markers on 16q, but not at 16p. The skin adnexal tumours showing a similar pattern included apocrine hydrocystomas, eccrine spiradenomas, and sebaceous adenoma. One case of syringoma showed LOH at 16q, and a further case at 16p, but not 16q. One case of eccrine hydrocystoma showed loss at 16p, but not 16q. The remaining tumours were either negative or non-informative. All tumours in the control group were either negative or non-informative, except for a single case of BCC showing LOH at 16q.
CONCLUSION: CYLD may be involved in the development of skin adnexal tumours other than cylindromas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533075      PMCID: PMC1731526          DOI: 10.1136/jcp.54.9.689

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  20 in total

1.  Identification of the familial cylindromatosis tumour-suppressor gene.

Authors:  G R Bignell; W Warren; S Seal; M Takahashi; E Rapley; R Barfoot; H Green; C Brown; P J Biggs; S R Lakhani; C Jones; J Hansen; E Blair; B Hofmann; R Siebert; G Turner; D G Evans; C Schrander-Stumpel; F A Beemer; A van Den Ouweland; D Halley; B Delpech; M G Cleveland; I Leigh; J Leisti; S Rasmussen
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Cytogenetics of a case of eccrine spiradenoma.

Authors:  T Dijkhuizen; E van den Berg; P G Nikkels; H J Hoekstra; B de Jong
Journal:  Hum Pathol       Date:  1992-09       Impact factor: 3.466

3.  Genetic alterations in 'normal' luminal and myoepithelial cells of the breast.

Authors:  S R Lakhani; R Chaggar; S Davies; C Jones; N Collins; C Odel; M R Stratton; M J O'Hare
Journal:  J Pathol       Date:  1999-12       Impact factor: 7.996

4.  Dermal cylindromas (turban tumour) and eccrine spiradenomas in a patient with membranous basal cell adenoma of the parotid gland.

Authors:  C Ferrándiz; E Campo; E Baumann
Journal:  J Cutan Pathol       Date:  1985-02       Impact factor: 1.587

Review 5.  Laser capture microdissection in pathology.

Authors:  F Fend; M Raffeld
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

Review 6.  Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes.

Authors:  J Yokota; T Sugimura
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

7.  Familial multiple desmoplastic trichoepitheliomas.

Authors:  P E Shapiro; A W Kopf
Journal:  Arch Dermatol       Date:  1991-01

8.  Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9.

Authors:  M R Gailani; S J Bale; D J Leffell; J J DiGiovanna; G L Peck; S Poliak; M A Drum; B Pastakia; O W McBride; R Kase
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

9.  Delineation of two distinct deleted regions on chromosome 9 in human non-melanoma skin cancers.

Authors:  A G Quinn; S Sikkink; J L Rees
Journal:  Genes Chromosomes Cancer       Date:  1994-12       Impact factor: 5.006

10.  Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss.

Authors:  A G Quinn; S Sikkink; J L Rees
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

View more
  13 in total

1.  Epidermal CYLD inactivation sensitizes mice to the development of sebaceous and basaloid skin tumors.

Authors:  Yingai Jane Jin; Sally Wang; Joshua Cho; M Angelica Selim; Tim Wright; George Mosialos; Jennifer Y Zhang
Journal:  JCI Insight       Date:  2016-07-21

Review 2.  Skin adnexal neoplasms--part 2: an approach to tumours of cutaneous sweat glands.

Authors:  Nidal A Obaidat; Khaled O Alsaad; Danny Ghazarian
Journal:  J Clin Pathol       Date:  2006-08-01       Impact factor: 3.411

3.  [Cylindromatosis].

Authors:  S Pfaff; M Megahed
Journal:  Hautarzt       Date:  2011-05       Impact factor: 0.751

4.  CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels.

Authors:  Paula Miliani de Marval; Shazia Lutfeali; Jane Y Jin; Benjamin Leshin; M Angelica Selim; Jennifer Y Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-08

5.  Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing.

Authors:  Nicola Fusco; Pierre-Emmanuel Colombo; Luciano G Martelotto; Maria R De Filippo; Salvatore Piscuoglio; Charlotte K Y Ng; Raymond S Lim; William Jacot; Anne Vincent-Salomon; Jorge S Reis-Filho; Britta Weigelt
Journal:  Histopathology       Date:  2015-06-29       Impact factor: 5.087

Review 6.  Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.

Authors:  Patrick W Blake; Jorge R Toro
Journal:  Hum Mutat       Date:  2009-07       Impact factor: 4.878

7.  Identification of a large rearrangement in CYLD as a cause of familial cylindromatosis.

Authors:  Ans M W van den Ouweland; Peter Elfferich; Roy Lamping; Raoul van de Graaf; Monique M van Veghel-Plandsoen; S M Franken; A C Houweling
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

8.  Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer.

Authors:  K C Masoumi; Gina Shaw-Hallgren; Ramin Massoumi
Journal:  J Skin Cancer       Date:  2011-12-17

9.  Metastatic syringoid eccrine carcinoma of the nipple.

Authors:  Pierluigi Ballardini; Guido Margutti; Massimo Pedriali; Patrizia Querzoli
Journal:  Int Med Case Rep J       Date:  2012-07-11

10.  The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.

Authors:  Alexandre Regamey; Daniel Hohl; Jia Wei Liu; Thierry Roger; Priit Kogerman; Rune Toftgard; Marcel Huber
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.